Danaher Corp DHR

$235.12 +4.87 (2.12%)

Valuation

Market cap
161,988,016,000
Revenue TTM
$24,568,000,000
Net income TTM
$3,614,000,000
P/E (trailing)
27.14
P/E (forward)
26.35
Profit margin
14.71%
Debt to equity
0.45

Trading

Volume
3,630,500
Avg volume
4,235,710
Day's range
$228.37 – $236.66
Shares out
703,531,000
Stochastic %K
78%
Beta
0.76
Analysts
Strong Buy
Price target
$257.05

Price

Company profile

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of...

Show more

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Industry
Diagnostics & Research
Sector
Healthcare
Phone
202 828 0850
Website
https://www.danaher.com
Address
2200 Pennsylvania Avenue N.W., Suite 800W, Washington, United States

Latest news

No headlines yet.

Stocktwits

Fair_Trader42 Nov 9, 8:14 PM
$DHR From todays conference call by CEO Julie.. M&A are still a strong focus, ... I think so TTOO
0 replies
11thestate Nov 5, 1:49 PM
If you missed the deadline, don’t miss this update. This is probably the most useful info you’ve read in years about $DHR how you can actually recover something: https://11th.com/cases/danaher-investor-settlement
0 replies
openclassaction2 Nov 1, 5:17 AM
$DHR: still holding Danaher shares on Jan. 19, 2024? In Hawkins, that slice is capped at purchase price minus $216.62, the 90-day average. Claims closed Sept. 20, approval pending. Open Class Actions.
0 replies
openclassaction2 Oct 30, 8:50 PM
$DHR: plaintiffs allege Danaher misled investors about its bioprocessing business. The $172.5M Hawkins deal is still awaiting final approval after the Sept. 3 hearing, claims closed. Open Class Actions.
0 replies
openclassaction2 Oct 29, 8:28 AM
$DHR: no check under $10 in Hawkins. The Plan of Allocation cuts off any Danaher claimant whose pro rata share of the $172.5M fund comes to less than $10. Claims closed, approval pending. Open Class Actions.
0 replies
openclassaction2 Oct 27, 9:13 PM
$DHR: filed in Hawkins? The wait is now on Judge Ali. The Sept. 3 fairness hearing is done, but no final approval order had been located as of Oct. 1, and no pay date is set. Claims closed. Open Class Actions.
0 replies
Snaggle_Puss Oct 26, 2:35 PM
$DHR and off we go!
0 replies
openclassaction2 Oct 26, 12:18 PM
$DHR: who was in Hawkins? Investors who bought Danaher stock Jan. 27, 2022 to Oct. 23, 2023. The $172.5M securities deal estimates about $1.13 per share, claims closed Sept. 20, payouts pending approval. Open Class Actions.
0 replies